• 1. An alternative biorefinery approach to address microalgal seasonality: blending with spent coffee grounds
  Andre Prates Pereira,Tao Dong,Eric P. Knoshaug,Nick Nagle,Ryan Spiller,Bonnie Panczak,Christopher J. Chuck,Philip T. Pienkos Sustainable Energy Fuels, 2020,4, 3400-3408
• 2. An anti-leakage liquid metal thermal interface material
  Kaiyuan Huang,Wangkang Qiu,Meilian Ou,Xiaorui Liu,Zenan Liao,Sheng Chu RSC Adv., 2020,10, 18824-18829
• 3. An algal process treatment combined with the Fenton reaction for high concentrations of amoxicillin and cefradine
  Haitao Li,Yu Pan,Zhizhi Wang,Shan Chen,Ruixin Guo,Jianqiu Chen RSC Adv., 2015,5, 100775-100782
• 4. An alumina stabilized graphene oxide wrapped SnO2 hollow sphere LIB anode with improved lithium storage?
  Xiang Liu,Qian Sun,A. B. Djuri?i?,Maohai Xie,Baohu Dai,Jinyao Tang,Charles Surya,Changzhong Liao,Kaimin Shih RSC Adv., 2015,5, 100783-100789
• 5. An anti-ultrasonic-stripping effect in confined micro/nanoscale cavities and its applications for efficient multiscale metallic patterning?
  Quan Xiang,Yiqin Chen,Zhiqin Li,Kaixi Bi,Guanhua Zhang,Huigao Duan Nanoscale, 2016,8, 19541-19550

Recent Advances in the Study of 5-Propyl-1,3,4-thiadiazol-2-amine (CAS: 39223-04-6) in Chemical Biology and Pharmaceutical Research

The compound 5-Propyl-1,3,4-thiadiazol-2-amine (CAS: 39223-04-6) has recently garnered significant attention in the field of chemical biology and pharmaceutical research due to its unique structural properties and potential therapeutic applications. This research briefing aims to provide a comprehensive overview of the latest findings related to this compound, focusing on its synthesis, biological activity, and potential applications in drug development.

Recent studies have highlighted the versatility of 5-Propyl-1,3,4-thiadiazol-2-amine as a scaffold for the development of novel bioactive molecules. Its thiadiazole core, coupled with the propylamine side chain, offers a promising platform for interactions with various biological targets. Researchers have explored its potential as an inhibitor of key enzymes involved in inflammatory and metabolic pathways, with preliminary results indicating significant efficacy in vitro.

One of the most notable advancements in the study of this compound is its application in the design of antimicrobial agents. A 2023 study published in the Journal of Medicinal Chemistry demonstrated that derivatives of 5-Propyl-1,3,4-thiadiazol-2-amine exhibited potent activity against a range of Gram-positive and Gram-negative bacteria, including multidrug-resistant strains. The mechanism of action appears to involve disruption of bacterial cell wall synthesis, making it a promising candidate for further development.

In addition to its antimicrobial properties, 5-Propyl-1,3,4-thiadiazol-2-amine has also been investigated for its potential in cancer therapy. Recent in vitro and in vivo studies have shown that certain derivatives of this compound can induce apoptosis in cancer cells by modulating the activity of key signaling pathways, such as the PI3K/Akt/mTOR cascade. These findings suggest that this compound could serve as a valuable lead for the development of targeted anticancer agents.

The synthesis and optimization of 5-Propyl-1,3,4-thiadiazol-2-amine derivatives have also been a focal point of recent research. Advances in synthetic methodologies, including the use of green chemistry approaches, have enabled the efficient production of a diverse array of derivatives with improved pharmacokinetic properties. These developments are critical for the translation of laboratory findings into clinically viable therapeutics.

Despite these promising results, challenges remain in the development of 5-Propyl-1,3,4-thiadiazol-2-amine-based drugs. Issues such as solubility, bioavailability, and potential off-target effects need to be addressed through further structural optimization and preclinical studies. However, the growing body of evidence supporting its therapeutic potential underscores the importance of continued research in this area.

In conclusion, 5-Propyl-1,3,4-thiadiazol-2-amine (CAS: 39223-04-6) represents a promising scaffold for the development of novel therapeutic agents. Its diverse biological activities and the recent advancements in its synthesis and application highlight its potential to address unmet medical needs. Future research should focus on overcoming the current limitations and advancing the compound through the drug development pipeline.

• 57235-50-4(2-Amino-5-cyclopropyl-1,3,4-thiadiazole)
• 100539-95-5(5-Undecyl-1,3,4-thiadiazol-2-amine)
• 52057-90-6(5-Pentyl-1,3,4-thiadiazol-2-amine)
• 14068-54-3(5-Butyl-1,3,4-thiadiazol-2-amine)
• 141187-32-8(5-(2,2-Dimethylpropyl)-1,3,4-thiadiazol-2-amine)
• 314030-99-4(1,3,4-Thiadiazol-2-amine, 5,5'-(1,5-pentanediyl)bis-)
• 52057-91-7(5-Hexyl-1,3,4-thiadiazol-2-amine)
• 52057-89-3(5-(2-methylpropyl)-1,3,4-thiadiazol-2-amine)
• 299937-30-7(5-(cyclopropylmethyl)-1,3,4-thiadiazol-2-amine)
• 299935-39-0(5-(Cyclopentylmethyl)-1,3,4-thiadiazol-2-amine)